These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 11016469

  • 1. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV, Edwards R, Ho S, Lau WY, Glazer G.
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI.
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
    Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P.
    Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
    [Abstract] [Full Text] [Related]

  • 6. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW, Tong KJ, Tam TN, Lee SD.
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [Abstract] [Full Text] [Related]

  • 7. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 8. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B.
    Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995 Sep; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 11. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG.
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [Abstract] [Full Text] [Related]

  • 12. Persistent elevation of serum CA 19-9 with no evidence of malignant disease.
    Ventrucci M, Pozzato P, Cipolla A, Uomo G.
    Dig Liver Dis; 2009 May; 41(5):357-63. PubMed ID: 18602352
    [Abstract] [Full Text] [Related]

  • 13. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G, Manabe T, Watanabe Y, Endo K, Kudo H, Suzuki T, Tobe T.
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [Abstract] [Full Text] [Related]

  • 14. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G, Teli M, Jardine N, Puntis MC.
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [Abstract] [Full Text] [Related]

  • 15. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
    Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, Nawata H, Watanabe T.
    Dig Liver Dis; 2004 Sep; 36(9):622-7. PubMed ID: 15460847
    [Abstract] [Full Text] [Related]

  • 16. The clinical significance of elevated levels of serum CA 19-9.
    Pavai S, Yap SF.
    Med J Malaysia; 2003 Dec; 58(5):667-72. PubMed ID: 15190651
    [Abstract] [Full Text] [Related]

  • 17. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB.
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [Abstract] [Full Text] [Related]

  • 18. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP.
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [Abstract] [Full Text] [Related]

  • 19. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA, Kauppinen R, Eskelinen M, Partanen K, Pikkarainen P, Alhava E.
    Anticancer Res; 1993 Jul; 13(3):763-8. PubMed ID: 8317910
    [Abstract] [Full Text] [Related]

  • 20. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K, Iwaki K, Kai S, Ohta M, Kitano S.
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.